- Consent to publish
The authors read and approved the final manuscript and agree to publish.
- Availability of data and materials
No further underlying research material is associated with this article.
- Competing interests
The author declares no competing interests.
- Funding
MOST: 105-2314-B-182-050-MY3 and MOST 106-2314-B-182A-156-MY3 from the
Ministry of Science and Technology of Taiwan and CMRPG8G0272 from Chang
Gung Memorial Hospital in Taiwan. Although these institutes provided
financial support, they had no influence on the way we collected,
analyzed, or interpreted the data or wrote this manuscript.
- Authors’ Contributions
YJS participated in draft the manuscript. HCK participated in its design
and coordination.
References:
1. Wang, H., et al., Neutrophil Extracellular Trap Mitochondrial
DNA and Its Autoantibody in Systemic Lupus Erythematosus and a
Proof-of-Concept Trial of Metformin. Arthritis Rheumatol, 2015.67 (12): p. 3190-200.
2. Liu, L., et al., Impact of diabetes mellitus on risk of
cardiovascular disease and all-cause mortality: Evidence on health
outcomes and antidiabetic treatment in United States adults. World J
Diabetes, 2016. 7 (18): p. 449-461.
3. Lin, C.C., et al., Accuracy of diabetes diagnosis in health
insurance claims data in Taiwan. J Formos Med Assoc, 2005.104 (3): p. 157-63.
4. Sung, S.F., et al., Validity of a stroke severity index for
administrative claims data research: a retrospective cohort study. BMC
Health Serv Res, 2016. 16 (1): p. 509.
5. Damjanov, N., M.T. Nurmohamed, and Z. Szekanecz, Biologics,
cardiovascular effects and cancer. BMC Med, 2014. 12 : p. 48.
6. Ursini, F., et al., The effect of non-TNF-targeted biologics
and small molecules on insulin resistance in inflammatory arthritis.Autoimmun Rev, 2018. 17 (4): p. 399-404.
7. Killinger, Z., et al., Biologic treatment in comparison to
methotrexate has positive effect on trabecular bone score in rheumatoid
arthritis patients: 1-year follow-up. Acta Clin Belg, 2018: p. 1-5.
8. Zerbini, C.A.F., et al., Biologic therapies and bone loss in
rheumatoid arthritis. Osteoporos Int, 2017. 28 (2): p. 429-446.
9. Maneiro, J.R., A. Souto, and J.J. Gomez-Reino, Risks of
malignancies related to tofacitinib and biological drugs in rheumatoid
arthritis: Systematic review, meta-analysis, and network meta-analysis.Semin Arthritis Rheum, 2017. 47 (2): p. 149-156.
10. Wilton, K.M. and E.L. Matteson, Malignancy Incidence,
Management, and Prevention in Patients with Rheumatoid Arthritis.Rheumatol Ther, 2017. 4 (2): p. 333-347.
11. Ramiro, S., et al., Safety of synthetic and biological DMARDs:
a systematic literature review informing the 2016 update of the EULAR
recommendations for management of rheumatoid arthritis. Ann Rheum Dis,
2017. 76 (6): p. 1101-1136.
12. Kourbeti, I.S., P.D. Ziakas, and E. Mylonakis, Biologic
therapies in rheumatoid arthritis and the risk of opportunistic
infections: a meta-analysis. Clin Infect Dis, 2014. 58 (12): p.
1649-57.
13. Furst, D.E., The risk of infections with biologic therapies
for rheumatoid arthritis. Semin Arthritis Rheum, 2010. 39 (5):
p. 327-46.
14. Barnabe, C., et al., Sex differences in pain scores and
localization in inflammatory arthritis: a systematic review and
metaanalysis. J Rheumatol, 2012. 39 (6): p. 1221-30.
15. Kamata, Y. and S. Minota, Wide difference in biologics usage
and expenditure for the treatment of patients with rheumatoid arthritis
in each prefecture in Japan analyzed using ”National Database of Health
Insurance Claims and Specific Health Checkups of Japan”. Rheumatol Int,
2018. 38 (4): p. 663-668.
16. Stoll, M.L. and A.C. Gotte, Biological therapies for the
treatment of juvenile idiopathic arthritis: Lessons from the adult and
pediatric experiences. Biologics, 2008. 2 (2): p. 229-52.
17. Borren, N.Z. and A.N. Ananthakrishnan, Safety of Biologic
Therapy in Older Patients with Immune-Mediated Diseases: A Systematic
Review and Meta-Analysis. Clin Gastroenterol Hepatol, 2019.
18. Singh, J.A., et al., Risk of serious infection in biological
treatment of patients with rheumatoid arthritis: a systematic review and
meta-analysis. Lancet, 2015. 386 (9990): p. 258-65.
19. Rutherford, A.I., et al., Opportunistic infections in
rheumatoid arthritis patients exposed to biologic therapy: results from
the British Society for Rheumatology Biologics Register for Rheumatoid
Arthritis. Rheumatology (Oxford), 2018. 57 (6): p. 997-1001.
20. Bruce, E.S., et al., Risk of Pneumocystis jirovecii pneumonia
in patients with rheumatoid arthritis treated with inhibitors of tumour
necrosis factor alpha: results from the British Society for Rheumatology
Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford),
2016. 55 (7): p. 1336-7.
21. Yun, H., et al., Risks of herpes zoster in patients with
rheumatoid arthritis according to biologic disease-modifying therapy.Arthritis Care Res (Hoboken), 2015. 67 (5): p. 731-6.
22. Salliot, C., M. Dougados, and L. Gossec, Risk of serious
infections during rituximab, abatacept and anakinra treatments for
rheumatoid arthritis: meta-analyses of randomised placebo-controlled
trials. Ann Rheum Dis, 2009. 68 (1): p. 25-32.
23. Liao, H., et al., Comparison of the risk of infections in
different anti-TNF agents: a meta-analysis. Int J Rheum Dis, 2017.20 (2): p. 161-168.
24. Hussain, M.I., et al., Acute renal failure and
metformin-associated lactic acidosis following colonoscopy. Diabetes
Res Clin Pract, 2014. 105 (1): p. e6-8.
25. Adam, W.R. and R.C. O’Brien, A justification for less
restrictive guidelines on the use of metformin in stable chronic renal
failure. Diabet Med, 2014. 31 (9): p. 1032-8.
26. Accortt, N.A., et al., Retrospective analysis to describe
associations between tumor necrosis factor alpha inhibitors and
COPD-related hospitalizations. Int J Chron Obstruct Pulmon Dis, 2017.12 : p. 2085-2094.
27. de La Forest Divonne, M., J.E. Gottenberg, and C. Salliot,Safety of biologic DMARDs in RA patients in real life: A
systematic literature review and meta-analyses of biologic registers.Joint Bone Spine, 2017. 84 (2): p. 133-140.
28. Hsu, C.S., et al., Risks of hepatocellular carcinoma and
cirrhosis-associated complications in patients with rheumatoid
arthritis: a 10-year population-based cohort study in Taiwan. Hepatol
Int, 2018. 12 (6): p. 531-543.
29. Scott, I.C., S.L. Hider, and D.L. Scott, Thromboembolism with
Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the
Risk? Drug Saf, 2018. 41 (7): p. 645-653.
30. Frost, A.E., et al., Giant cell interstitial pneumonitis.
Disease recurrence in the transplanted lung. Am Rev Respir Dis, 1993.148 (5): p. 1401-4.
31. Holdsworth, S., et al., The clinical spectrum of acute
glomerulonephritis and lung haemorrhage (Goodpasture’s syndrome). Q J
Med, 1985. 55 (216): p. 75-86.
32. England, B.R., et al., Chronic lung disease in U.S. Veterans
with rheumatoid arthritis and the impact on survival. Clin Rheumatol,
2018. 37 (11): p. 2907-2915.
33. Fernandez-Diaz, C., et al., Abatacept in patients with
rheumatoid arthritis and interstitial lung disease: A national
multicenter study of 63 patients. Semin Arthritis Rheum, 2018.48 (1): p. 22-27.
34. Druce, K.L., et al., Mortality in patients with interstitial
lung disease treated with rituximab or TNFi as a first biologic. RMD
Open, 2017. 3 (1): p. e000473.
35. Roubille, C. and B. Haraoui, Interstitial lung diseases
induced or exacerbated by DMARDS and biologic agents in rheumatoid
arthritis: a systematic literature review. Semin Arthritis Rheum, 2014.43 (5): p. 613-26.